Gene therapy technology (CD9 siRNA) that realizes innovative angiogenesis inhibitors!
We would like to introduce our "angiogenesis inhibitor" that suppresses CD9 expression (siRNA). Results from validation using a rat corneal model showed that the suppression of CD9 expression significantly inhibited both the motility and invasiveness of endothelial cells. Additionally, the angiogenesis inhibitory effect was confirmed in both pathways involving different angiogenic factors (HGF and VEGF). [Key Points] ■ Confirmed significant suppression of motility and invasiveness in vitro ■ Clear angiogenesis inhibitory effect confirmed in vivo ■ An angiogenesis inhibitor with universal effects against different angiogenic factors *For more details, please download the PDF or feel free to contact us.
Inquire About This Product
basic information
For more details, please download the PDF or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please download the PDF or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Since our establishment, we have been supporting the commercialization of various companies. We have extensive experience and achievements in commercializing technologies developed at universities and launching new businesses utilizing subsidies. We will introduce researchers and technology seeds suitable for your company's product/technology development/research. Please feel free to contact us.